Briefly, mutations in BRAF, an up-stream regulator of mitogen-activated protein kinase enzymes (MEK), causes dysregulated activation of MEK, promoting cellular proliferation and cancer through the well-described RAS-MEK-ERK1/2 pathway. Here, MAP2K7 is linked to cancer.